Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction

Lea Cunningham, Steven Finckbeiner, Ricia K Hyde, Noel Southall, Juan Marugan, Venkat R.K. Yedavalli, Seameen Jean Dehdashti, William C. Reinhold, Lemlem Alemu, Ling Zhao, Jing Ruey Joanna Yeh, Raman Sood, Yves Pommier, Christopher P. Austin, Kuan Teh Jeang, Wei Zheng, Paul Liu

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Core binding factor (CBF) leukemias, those with translocations or inversions that affect transcription factor genes RUNX1 or CBFB, account for ∼24% of adult acute myeloid leukemia (AML) and 25% of pediatric acute lymphocytic leukemia (ALL). Current treatments for CBF leukemias are associated with significant morbidity and mortality, with a 5-y survival rate of ∼50%. We hypothesize that the interaction between RUNX1 and CBFβ is critical for CBF leukemia and can be targeted for drug development. We developed high-throughput AlphaScreen and time-resolved fluorescence resonance energy transfer (TR-FRET) methods to quantify the RUNX1-CBFβ interaction and screen a library collection of 243,398 compounds. Ro5-3335, a benzodiazepine identified from the screen,was able to interact with RUNX1 and CBFβ directly, repress RUNX1/CBFB-dependent transactivation in reporter assays, and repress runx1-dependent hematopoiesis in zebrafish embryos. Ro5-3335 preferentially killed human CBF leukemia cell lines, rescued preleukemic phenotype in a RUNX1-ETO transgenic zebrafish, and reduced leukemia burden in amouse CBFB-MYH11 leukemia model. Our data thus confirmed that RUNX1-CBFβ interaction can be targeted for leukemia treatment and we have identified a promising lead compound for this purpose.

Original languageEnglish (US)
Pages (from-to)14592-14597
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number36
DOIs
StatePublished - Sep 4 2012

Fingerprint

Core Binding Factors
Benzodiazepines
Leukemia
Zebrafish
Fluorescence Resonance Energy Transfer
Hematopoiesis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Transcriptional Activation
Libraries
Transcription Factors
Embryonic Structures
Survival Rate
Pediatrics
Morbidity
Phenotype
Cell Line

ASJC Scopus subject areas

  • General

Cite this

Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction. / Cunningham, Lea; Finckbeiner, Steven; Hyde, Ricia K; Southall, Noel; Marugan, Juan; Yedavalli, Venkat R.K.; Dehdashti, Seameen Jean; Reinhold, William C.; Alemu, Lemlem; Zhao, Ling; Yeh, Jing Ruey Joanna; Sood, Raman; Pommier, Yves; Austin, Christopher P.; Jeang, Kuan Teh; Zheng, Wei; Liu, Paul.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 36, 04.09.2012, p. 14592-14597.

Research output: Contribution to journalArticle

Cunningham, L, Finckbeiner, S, Hyde, RK, Southall, N, Marugan, J, Yedavalli, VRK, Dehdashti, SJ, Reinhold, WC, Alemu, L, Zhao, L, Yeh, JRJ, Sood, R, Pommier, Y, Austin, CP, Jeang, KT, Zheng, W & Liu, P 2012, 'Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction', Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 36, pp. 14592-14597. https://doi.org/10.1073/pnas.1200037109
Cunningham, Lea ; Finckbeiner, Steven ; Hyde, Ricia K ; Southall, Noel ; Marugan, Juan ; Yedavalli, Venkat R.K. ; Dehdashti, Seameen Jean ; Reinhold, William C. ; Alemu, Lemlem ; Zhao, Ling ; Yeh, Jing Ruey Joanna ; Sood, Raman ; Pommier, Yves ; Austin, Christopher P. ; Jeang, Kuan Teh ; Zheng, Wei ; Liu, Paul. / Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction. In: Proceedings of the National Academy of Sciences of the United States of America. 2012 ; Vol. 109, No. 36. pp. 14592-14597.
@article{fcb71ced0ba64b35857cbb7f5cbf207c,
title = "Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction",
abstract = "Core binding factor (CBF) leukemias, those with translocations or inversions that affect transcription factor genes RUNX1 or CBFB, account for ∼24{\%} of adult acute myeloid leukemia (AML) and 25{\%} of pediatric acute lymphocytic leukemia (ALL). Current treatments for CBF leukemias are associated with significant morbidity and mortality, with a 5-y survival rate of ∼50{\%}. We hypothesize that the interaction between RUNX1 and CBFβ is critical for CBF leukemia and can be targeted for drug development. We developed high-throughput AlphaScreen and time-resolved fluorescence resonance energy transfer (TR-FRET) methods to quantify the RUNX1-CBFβ interaction and screen a library collection of 243,398 compounds. Ro5-3335, a benzodiazepine identified from the screen,was able to interact with RUNX1 and CBFβ directly, repress RUNX1/CBFB-dependent transactivation in reporter assays, and repress runx1-dependent hematopoiesis in zebrafish embryos. Ro5-3335 preferentially killed human CBF leukemia cell lines, rescued preleukemic phenotype in a RUNX1-ETO transgenic zebrafish, and reduced leukemia burden in amouse CBFB-MYH11 leukemia model. Our data thus confirmed that RUNX1-CBFβ interaction can be targeted for leukemia treatment and we have identified a promising lead compound for this purpose.",
author = "Lea Cunningham and Steven Finckbeiner and Hyde, {Ricia K} and Noel Southall and Juan Marugan and Yedavalli, {Venkat R.K.} and Dehdashti, {Seameen Jean} and Reinhold, {William C.} and Lemlem Alemu and Ling Zhao and Yeh, {Jing Ruey Joanna} and Raman Sood and Yves Pommier and Austin, {Christopher P.} and Jeang, {Kuan Teh} and Wei Zheng and Paul Liu",
year = "2012",
month = "9",
day = "4",
doi = "10.1073/pnas.1200037109",
language = "English (US)",
volume = "109",
pages = "14592--14597",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "36",

}

TY - JOUR

T1 - Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction

AU - Cunningham, Lea

AU - Finckbeiner, Steven

AU - Hyde, Ricia K

AU - Southall, Noel

AU - Marugan, Juan

AU - Yedavalli, Venkat R.K.

AU - Dehdashti, Seameen Jean

AU - Reinhold, William C.

AU - Alemu, Lemlem

AU - Zhao, Ling

AU - Yeh, Jing Ruey Joanna

AU - Sood, Raman

AU - Pommier, Yves

AU - Austin, Christopher P.

AU - Jeang, Kuan Teh

AU - Zheng, Wei

AU - Liu, Paul

PY - 2012/9/4

Y1 - 2012/9/4

N2 - Core binding factor (CBF) leukemias, those with translocations or inversions that affect transcription factor genes RUNX1 or CBFB, account for ∼24% of adult acute myeloid leukemia (AML) and 25% of pediatric acute lymphocytic leukemia (ALL). Current treatments for CBF leukemias are associated with significant morbidity and mortality, with a 5-y survival rate of ∼50%. We hypothesize that the interaction between RUNX1 and CBFβ is critical for CBF leukemia and can be targeted for drug development. We developed high-throughput AlphaScreen and time-resolved fluorescence resonance energy transfer (TR-FRET) methods to quantify the RUNX1-CBFβ interaction and screen a library collection of 243,398 compounds. Ro5-3335, a benzodiazepine identified from the screen,was able to interact with RUNX1 and CBFβ directly, repress RUNX1/CBFB-dependent transactivation in reporter assays, and repress runx1-dependent hematopoiesis in zebrafish embryos. Ro5-3335 preferentially killed human CBF leukemia cell lines, rescued preleukemic phenotype in a RUNX1-ETO transgenic zebrafish, and reduced leukemia burden in amouse CBFB-MYH11 leukemia model. Our data thus confirmed that RUNX1-CBFβ interaction can be targeted for leukemia treatment and we have identified a promising lead compound for this purpose.

AB - Core binding factor (CBF) leukemias, those with translocations or inversions that affect transcription factor genes RUNX1 or CBFB, account for ∼24% of adult acute myeloid leukemia (AML) and 25% of pediatric acute lymphocytic leukemia (ALL). Current treatments for CBF leukemias are associated with significant morbidity and mortality, with a 5-y survival rate of ∼50%. We hypothesize that the interaction between RUNX1 and CBFβ is critical for CBF leukemia and can be targeted for drug development. We developed high-throughput AlphaScreen and time-resolved fluorescence resonance energy transfer (TR-FRET) methods to quantify the RUNX1-CBFβ interaction and screen a library collection of 243,398 compounds. Ro5-3335, a benzodiazepine identified from the screen,was able to interact with RUNX1 and CBFβ directly, repress RUNX1/CBFB-dependent transactivation in reporter assays, and repress runx1-dependent hematopoiesis in zebrafish embryos. Ro5-3335 preferentially killed human CBF leukemia cell lines, rescued preleukemic phenotype in a RUNX1-ETO transgenic zebrafish, and reduced leukemia burden in amouse CBFB-MYH11 leukemia model. Our data thus confirmed that RUNX1-CBFβ interaction can be targeted for leukemia treatment and we have identified a promising lead compound for this purpose.

UR - http://www.scopus.com/inward/record.url?scp=84865960664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865960664&partnerID=8YFLogxK

U2 - 10.1073/pnas.1200037109

DO - 10.1073/pnas.1200037109

M3 - Article

VL - 109

SP - 14592

EP - 14597

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 36

ER -